Jon Isaacsohn, CinRx CEO

Ex­clu­sive: Gas­tro­pare­sis biotech Cin­Dome se­cures $40M for path to piv­otal tri­al

A gas­tro­pare­sis biotech from the cre­ator of Cin­Cor Phar­ma, the hy­per­ten­sion biotech bought by As­traZeneca for $1.8 bil­lion last year, has raised …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.